Tag Archives: stage 4

fightcrc-researchupdate-tas-102

Another treatment option coming down the pike: TAS-102

Another treatment option coming down the pike: TAS-102

Fight Colorectal Cancer stays actively involved in the research process from beginning to end. Part of our role in research is monitoring the progress of new drugs – drugs that may be used in treatment plans of colorectal cancer in the future. We actively work with drug companies to stay up-to-date on the latest treatments so that we can let patients and families know what’s happening in the science of colorectal cancer. For the last year, Fight Colorectal Cancer staff have tracked the progress of the drug TAS-102 – an oral chemo drug currently being evaluated in clinical trials for patients with metastatic refractory colorectal cancer. At the ESMO World

guidethefight

Fight Colorectal Cancer Releases “Guide in the Fight” Resource Book for Stage III & Stage IV Colorectal Cancer Patients

FOR IMMEDIATE RELEASE ALEXANDRIA, Va., June 17, 2014 – Today Fight Colorectal Cancer released its new patient education resource, Your Guide in the Fight. Your Guide in the Fight answers common questions and provides practical tips for those fighting stage III and stage IV colorectal cancer (advanced stage disease.) The resource walks patients through a cancer diagnosis step-by-step, covering topics ranging from second opinions, clinical trials, financial assistance, intimacy issues, ostomy support, hospice, survivorship and more. The book is written to assist patients and caregivers from the first day of diagnosis to the last day of treatment.   A 10-step, 65 Page workbook, the Guide provides information about medical terms,

First-Line Treatment Approved for Stage IV Colorectal Cancer

There is new first-line treatment (standard of care to start treatment) giving as many as 60% of the stage IV colorectal cancer patients more options for treatment. Previously, most stage IV patients undergoing chemotherapy would be recommended to go on FOLFOX and bevacizumab (Avastin). Patients would receive this first set of drugs (called first-line) and if the cancer continued to grow, then other treatment options would be explored. Recently, the FDA approved an additional drug to be used as a first-line option for some stage IV patients. But this is for a specific set of patients based on their tumor gene type, known as biomarker. The new targeted therapy panitumumab

Top